FinPharma brings together the pharmaceutical drug research of the University of Helsinki, the University of Eastern Finland, and Åbo Akademi University. FinPharma kick-off webinar on 21 October presents the new researchers and their research themes.
Come and join the FinPharma Finnish Platform for Pharmaceutical Research kick-off webinar on 21 October 2020, 13:00–16:00! In the webinar the brand new FinPharma researchers present their research subjects.
The webinar is for free.
PROGRAMME 21 October 2020 (subject to change)
| 13:00–13:30 | Opening of the kick-off event, Jouni Hirvonen, Dean, Faculty of Pharmacy, University of Helsinki |
| Greetings from the University of Helsinki, Paula Eerola, Vice-Rector | |
| Greetings from the University of Eastern Finland, Jarkko Ketolainen, Professor | |
| Greetings from the Åbo Akademi University, Jessica Rosenholm, Professor | |
| A brief history of FinPharma, Jari Yli-Kauhaluoma, FinPharma Director, Faculty of Pharmacy, University of Helsinki | |
| 13:30–13:50 | Biologics as by-products of vascular biology research, Michael Jeltsch, Associate Professor in Pharmaceutical Protein Drug Research, University of Helsinki |
| 13:50–14:10 | Human-on-a-chip – More methodological diversity for development of medical treatments, Tiina Sikanen, Associate Professor in Pharmacometabolomics, University of Helsinki |
| 14:10–14:30 | Modulation of proteostasis as therapeutic strategy for stroke and neurodegeneration, Mikko Airavaara, Professor in Pharmacology and Drug Development, University of Helsinki |
| 14:30–14:50 | Shining a guiding light for medical Uber deliveries – Active targeting and drug release at diseased site, Tatu Lajunen, University Researcher (Targeted Delivery Technologies for Biomacromolecules), University of Helsinki & University of Eastern Finland |
| 14:50–15:10 | RNA interference and RNA activation as drug targets, Piia Kokkonen, University Researcher (Computer-aided drug design), University of Eastern Finland |
| 15:10–15:30 | Can we halt and reverse neurodegeneration? Merja Voutilainen, Assistant Professor in Regenerative Pharmacology, University of Helsinki |
| 15:30–16:00 | Closing words |